| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers B > Headlines for Boston Scientific Corp. > News item |
Boston Scientific study demonstrates PASV Valve technology reduces occlusion, infection
By Lisa Kerner
Erie, Pa., Jan. 18 - Boston Scientific Corp. announced the results of a five-year retrospective study on peripherally inserted central catheters with Pressure Activated Safety Valve (PASV) technology, indicating a significant reduction in rates of both occlusion (closure) and infection.
The study, conducted by Vanderbilt University Medical Center, collected data on more than 12,500 catheter procedures performed by trained personnel in Vanderbilt's specialized peripherally inserted central catheters nursing program, according to a company news release.
Analysis revealed that overall, the chance for either occlusion or infection was 2.24 times lower when patients received peripherally inserted central catheters with PASV Valve technology.
"This comprehensive study is another important step in establishing the clinical advantages of Boston Scientific's PASV Valve technology products," Dave McClellan, president, Boston Scientific's Oncology business, stated in the release. "The positive results should reinforce clinician confidence in using PASV Valve technology to deliver and maintain critical treatments to patients."
Peripherally inserted central catheters provide reliable access to the blood stream for patients requiring intravenous antibiotics, total parenteral nutrition, chemotherapy, blood products and blood sampling.
The U.S. market for the devices is currently estimated at $130 million with an annual growth rate
of approximately 20%, said the company.
Boston Scientific, based in Natick, Mass., offers a family of pressure activated safety valve products.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.